

Possible plant-based solutions for skin yeast infections

Ana I. Lopes, Maria M. Pintado and Freni K. Tavaría*

Centro de Biotecnologia e Química Fina – Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa/Porto, Rua Diogo Botelho, 1327, 4169-005 Porto, Portugal.

* Corresponding author: ftavaria@ucp.pt (Freni Kekhasharú Tavaría), telephone: +351 226196200.

Abstract

Skin, hair, and nail fungal infections affect almost a billion people globally and their incidence is rising. *Candida* spp. and *Malassezia* spp., two yeasts that are part of the skin microbiota, normally do not cause disease. But, when dysbiosis occurs and the skin microbiome is disturbed, they can become pathogenic. There are conventional antifungals that treat candidiasis and *Malassezia* infections, such as azoles and allylamines, among others. However, the limitations of these treatments (resistance, side effects) lead to the search for new, alternative, and natural drugs, such as plant extracts (PEs) and essential oils (EOs). But these substances present some limitations (poor bioavailability and poor target capacity), which limits their efficiency. Their incorporation in formulations such as films and hydrogels (HGs) can help overcome these issues and may be a potential alternative to the current treatments. The main objective of this work is to provide a state-of-the-art review on *Candida* spp., *Malassezia* spp., mucocutaneous candidiasis and *Malassezia* infections, the conventional existing treatments and the incorporation of PEs and EOs in films and hydrogels as possible new alternative treatments for these diseases.

Keywords: *Candida* spp.; *Malassezia* spp.; films; hydrogels; essential oils; plant extracts¹

¹ Abbreviations:

PEs - plant extracts

EOs - essential oils

HG - hydrogel

29 1. Introduction

30

31 Skin is the largest organ in the human body representing approximately 15% of
32 the total body mass (Tchemtchoua et al., 2011) and is composed by three main layers.
33 The outer layer (epidermis) is a cellular stratified structure responsible for the barrier
34 function of the skin, mainly composed by keratinocytes. Between the epidermis and the
35 dermis there is a membrane made of collagen, elastin, hyaluronan and proteoglycans
36 responsible for skin's elasticity and mechanical resistance. The dermis, the second layer
37 of the skin, is composed of fibroblasts that synthesize extracellular matrix components
38 and endothelial cells that form blood vessels. The deepest layer of the skin, the
39 hypodermis, possesses adipose tissue and is well vascularized, playing a role in the skin
40 thermoregulatory and mechanical properties (Tchemtchoua et al., 2011).

41 The main function of the skin is to serve as barrier between our internal
42 physiological environment and the exterior, preventing our body to be invaded by
43 pathogenic microorganisms and protecting it from UV rays' exposure. It also plays a role
44 in limiting the evaporation of water from the body, thus contributing to control our
45 internal temperature (Gupta et al., 2012; Kozłowska et al., 2020).

46 Skin also has its own microbiota comprised by millions of bacteria, fungi and
47 viruses that also covers its appendages and glands. The bacterial communities found on
48 the skin are usually formed by bacteria belonging to the phyla Actinobacteria, Firmicutes,
49 Bacteroidetes and Proteobacteria (Grice and Segre, 2011). Although some inter-
50 variability and intra-variability exists, the dominant genera of skin bacteria are
51 *Staphylococcus*, *Propionibacterium* and *Corynebacterium* and, less frequently,
52 *Streptococcus* and *Pseudomonas* (Byrd et al., 2018; Grice and Segre, 2011). Regarding
53 the fungal skin microbiome, yeasts belonging to the genus *Malassezia* are the main
54 component of this community. Nevertheless, species belonging to genera *Cryptococcus*
55 spp. *Rhodotorula* spp. and *Candida* spp. can also be present (Boxberger et al., 2021).

56 Mites from genus *Demodex* are also part of the eukaryotic organisms living on
57 the skin (Boxberger et al., 2021). Viruses are also found on the skin and bacteriophages
58 are the predominant ones. Other common viruses are Densovirus, Alphapapillomavirus,
59 Human papillomavirus, Merkel cell polyomavirus, Molluscum contagiosum virus,
60 Polyomavirus HPyV7, Polyomavirus, HpyV6 RD114 retrovirus and Simian virus.
61 Papillomaviruses (Hannigan and Grice, 2013).

62 The skin microbiome varies with the body site. In oily sites bacteria from genera
63 *Staphylococcus* and *Corynebacterium* dominate, whereas on dry sites *Corynebacteria*,
64 *Flavobacteriales*, or β -*Proteobacteria* are the most abundant genera. Regarding the
65 fungal microbiome, *Malassezia* spp. are usually found at the core body and arm sites. In
66 the feet, more fungal species can be found, including *Aspergillus* spp., *Rhodotorula* spp.,
67 *Epicoccum* spp., *Malassezia* spp., and others (Fernandes et al., 2023).

68 Skin microbial communities play an important role in the protection from
69 pathogens invasion, regulation of local pH and rapid response to sudden environmental
70 changes (Pereira et al., 2017). However, when the skin barrier is broken or when the
71 delicate equilibrium between commensals and pathogens is disturbed (dysbiosis), it can
72 result in a skin disease (Byrd et al., 2018). In fact, this condition is associated with several
73 diseases, some pathological (acne with the loss of phylotype diversity of *Cutibacterium*
74 *acnes* (*C. acnes*) and atopic dermatitis with the increase in pathogenic *Staphylococcus*
75 *aureus* and commensal *S. epidermidis*; others non-pathogenic, (sensitive and dry skin) or
76 intensifying other skin disorders (psoriasis) (Byrd et al., 2018; Fournière et al., 2020).

77 Nowadays, skin diseases are an emerging concern affecting millions of people
78 every day. They are mainly caused by infectious agents or inflammatory situations and
79 can range in severity from benign to life threatening. The severity of the dermatological
80 condition depends on the type of pathogens involved, the integrity of the skin layers and
81 structures and the underlying medical condition of the patient (Gupta et al., 2012). Several
82 factors can be pointed out for the emergence of skin diseases, such as, environmental
83 reasons, lifestyle changes, urbanization, widespread use of cosmetics, globalization and
84 travel, antibiotic resistance, stress and mental health, changes in hygiene practices and
85 aging population (English et al., 2003; Singh and Schikowski, 2023). Despite the great
86 scientific progress in the treatment of dermatological conditions, many skin-related
87 diseases are still difficult to solve. The effective treatment of skin disorders demands
88 timely identification and management of the causative agent, choosing the most efficient
89 treatment and the optimal administration route with an optimized dosing schedule (Gupta
90 et al., 2012).

91 Conventional treatments for skin diseases, usually administered in the form of
92 ointments and creams, need to be applied in high concentrations due to the low efficiency
93 of the common delivery systems. This may result in toxic reactions such as skin irritation
94 and allergies. Furthermore, they present other disadvantages such as greasiness and

95 stickiness, as well as an uncontrolled evaporation of the active ingredient that causes an
96 unpleasant smell (Gupta et al., 2012).

97 This review will focus on essential oils (EOs) and plant extracts (PEs) for the
98 treatment of fungal infections by *Candida* spp. and *Malassezia* spp. It will also provide a
99 state-of-the-art review on films and hydrogels as biodegradable formulations for the
100 delivery of EOs and PEs to the skin.

101

102 **2. Skin yeast infections**

103

104 Skin, hair, and nail fungal infections affect almost a billion people globally. Of
105 these, more than 150 million people are affected with serious fungal infections that if left
106 untreated, can evolve into systemic diseases, thus impacting their lives significantly or
107 becoming fatal (Bongomin et al., 2017). The incidence and prevalence of each fungal
108 infection depends on the socio-economic conditions, geographic region and cultural
109 habits (Brown et al., 2012). The increasing number of people with HIV/AIDS,
110 tuberculosis, chronic obstructive pulmonary disease, asthma, and cancer is responsible
111 for the rise in the incidence and prevalence of fungal diseases across the world. The
112 severity of fungal infections ranges from asymptomatic-mild mucocutaneous infections
113 to potentially life-threatening systemic diseases, resulting in a mortality rate similar to
114 that of tuberculosis and 3-fold more than malaria (Bongomin et al., 2017).

115 *Candida* spp. is a group of commensal yeasts usually found on the skin and
116 mucous membranes of humans and animals (Bona et al., 2016). The genus *Candida*
117 comprises more than 200 species, some of which are found in several body sites and
118 secretions, (de Abreu et al., 2016), as part of the commensal microbiota. However, some
119 species are pathogenic, being responsible for many diseases that represent a risk for
120 human health (Bonifácio et al., 2015). Normally, the proliferation of these
121 microorganisms is controlled by the host immune system, and they do not cause disease
122 in healthy individuals. But, in immunocompromised patients or when microbial dysbiosis
123 is present, they can become pathogenic (Bona et al., 2016; de Abreu et al., 2016; Höfling,
124 José Francisco Puppim et al., 2019; Rai et al., 2017). Diabetes, immunosuppression,
125 damage of the stratum corneum, wet conditions, occlusion, obesity, Cushing's syndrome
126 and hormonal diseases are predisposing factors for candidiasis. Infants, pregnant women
127 and elderly people are more likely to suffer from this disease (Rai et al., 2017).

128 *Candida* spp. is responsible for most of the invasive fungal infections all over the
129 world. Mucocutaneous candidiasis is a very common fungal infection (M et al., 2020); it
130 normally involves the skin folds in axillae, inguinal, genital and perigenital areas, hands,
131 fingernails, skin beneath the breasts in women and mucous membranes (Rai et al., 2017).
132 The most common etiological agent is *Candida albicans* (*C. albicans*), accounting for
133 80-90% of the cases (Talapko et al., 2021). However, *Candida tropicalis* (*C. tropicalis*),
134 *Candida glabrata* (*C. glabrata*), *Candida parapsilosis* (*C. parapsilosis*), *Candida krusei*
135 (*C. krusei*) and *Candida guilliermondii* (*C. guilliermondii*) can also be responsible (Rai
136 et al., 2017). The main symptoms are erythema, erosions and cheesy white plates that are
137 mostly frequent on mucosal tissues. In the intertriginous zones, such as submammary,
138 inguinal folds, intergluteal creases, and pannus folds in overweight patients, the disease
139 manifests as erythematous patches, sometimes erosive with light scaling on the surface
140 and papules and pustules on the periphery (Talapko et al., 2021). *C. albicans* and *C.*
141 *tropicalis* can also be responsible for onychomycosis or tinea unguium, infections that
142 affect the nails or cause nails' dysfunction (Kumar et al., 2014).

143 Yeasts belonging to the genus *Malassezia* are the dominant eukaryotic colonizers
144 of the skin, being more abundant on the sebaceous sites, such as scalp, face, chest and
145 upper back, and less abundant on the trunk, arms and feet (Chandra et al., 2021). Usually,
146 they grow and do not cause any disease due to a strict balance between the immune system
147 and the skin microbiome. However, when this equilibrium is disturbed, due to
148 dysfunctional skin barrier, genetic background or environmental factors, they can become
149 pathogenic (Pedrosa et al., 2014; Saunders et al., 2012).

150 *Malassezia*-caused diseases are usually not life threatening but constitute one of the
151 most common diseases of the humankind (White et al., 2014). These skin conditions are
152 either caused by these microorganisms or exacerbated by them in a changing skin
153 environment (Chandra et al., 2021). Table 1 lists the diseases caused by *Malassezia*, the
154 area(s) of the body affected, some characteristics/ symptoms of these conditions, and the
155 responsible species.

156

157 **2.1. *Candida* spp. and *Malassezia* spp. virulence factors**

158

159 Both *Candida* spp. and *Malassezia* spp. are commensal colonizers of the skin that
160 only cause disease when the host immunity is compromised. For these microorganisms

161 to become pathogenic and invade the skin, they need to produce several virulence factors
162 (Figure 1).

163 The ability of *Candida* spp. to invade human tissues and cause disease depends
164 on the 1) expression of adhesion proteins and hydrolytic enzymes; 2) characteristics of
165 the cell wall; 3) morphological modification from yeast to pseudohyphal and hyphal
166 forms; and 4) biofilm formation capability (Bona et al., 2016; Höfling, José Francisco
167 Puppini et al., 2019) while for *Malassezia* spp., the principal characteristics that contribute
168 for their pathogenicity are their lipolytic activity, special cell wall construction, hyphae
169 formation/ biofilm formation and pigment production (Hort and Maysner, 2010)

170

171 **2.2. Available conventional treatments**

172

173 Cutaneous candidiasis is usually treated with topical antifungal drugs in the form
174 of creams, gels, and solutions. The regular application of the antifungal for at least a few
175 weeks is necessary for the complete cure of the infection. In immunosuppressed patients
176 and in the case of widespread lesions and deep infections of the scalp, it is necessary to
177 use systemic antifungals in combination with the topical ones (Rai et al., 2017). Azole
178 drugs, such as econazole, clotrimazole, ketoconazole, and miconazole and polyene
179 antifungals, such as nystatin, amphotericin B, and natamycin are usually used (Hay,
180 2018). *Candida* infections of the groins and inframammary folds are treated topically with
181 azole or polyenes creams for at least 2 weeks. It is also important to dry the infected area
182 because the skin moisture can cause discomfort (Hay, 2018). Onychomycosis by *Candida*
183 can be treated with antifungals, such as itraconazole, fluconazole or ketoconazole, or by
184 chemical removal, i.e., removal of the diseased and damaged part of nail alone, followed
185 by local antifungal therapy. If these treatments do not work, avulsion (i.e., chemical
186 destruction of the nail plate) and antifungal therapy must be used. Chronic
187 mucocutaneous candidiasis must be treated with itraconazole and the daily dose can be
188 increased to 200 mg. The treatment should be stopped when the remission is achieved.
189 *Candida paronychia* is frequently aggravated by bacterial infections of the nail fold and
190 irritant agents or contact dermatitis. In this case, the treatment consists of oral or topical
191 antifungals and topical corticosteroids. But this condition often relapses since the swollen
192 nail fold is a way for microbes and irritant substances to penetrate the skin. This situation

193 can be fixed through surgery that removes the fibrotic tissue that is found in chronic nail
194 swelling (Hay, 2018).

195 There are several studies on the antifungal activity of commonly used drugs upon
196 *Candida* species *in vitro*. Table 2 lists the minimum inhibitory concentrations (MICs) of
197 six of these antifungal agents.

198 Because *Malassezia* spp. can cause a series of diseases, the antifungal treatment to be
199 used will depend on the infection type. Several studies did an *in vitro* determination of
200 the antifungal activity of the most common drugs used against *Malassezia* species. In
201 Table 3, a list of MICs of seven antifungal agents commonly used upon 5 *Malassezia*
202 species is presented.

203 There are several antifungal therapies to treat *Malassezia* caused diseases (see
204 Supplementary table 1). Usually, topical antifungal drugs are used for the management
205 of localized skin diseases, while extensive disorders require administration of systemic
206 antifungals (Velegaki et al., 2015).

207

208 **2.3. Problems with the current treatments for skin yeast infections: side** 209 **effects and antifungal resistance**

210

211 The current treatments for mucocutaneous candidiasis and *Malassezia* infections
212 present a series of undesirable side effects. Azole antifungals, such as miconazole, present
213 increased burning, itching and irritation of the skin. Econazole can cause burning, itching
214 and redness too, while ketoconazole presents adverse effects such as itching, stinging, dry
215 skin and dry or oily scalp. The polyene antifungal nystatin has side effects that include
216 burning, itching and skin rash. It can also cause eye irritation, redness and generalized
217 pustular eruption (Rai et al., 2017).

218 Systemic antifungals have more severe adverse side effects. Fluconazole and
219 itraconazole can cause headache, dizziness, diarrhea, stomach pain, heartburn, changes in
220 the ability to taste food, excessive tiredness, loss of appetite, upset stomach, vomiting,
221 tingling or numbness in the extremities, fever, chills, exanthema, urticaria, angioedema
222 and difficulty swallowing. Terbinafine has similar adverse effects to those of triazoles.
223 These antifungal drugs cannot be used by pregnant and breastfeeding women and must
224 be used with caution in patients with severe hepatic and renal insufficiency and in children
225 (Rai et al., 2017).

226 Resistance to antifungal drugs is also a problem that has been arising in yeast
227 infections (Rai et al., 2017). The main cause for the appearance of resistant yeast strains
228 is the irregular use of antifungal drugs by patients, that often shorten the duration of the
229 treatment which does not allow the complete elimination of the pathogenic agent. As
230 such, the reinfection by fungal strains that became resistant to the antifungal drugs may
231 occur, as well as the subsequent reinfection with different infectious strains that were not
232 present in the first infection (Rai et al., 2017). Fungi developed a variety of mechanisms
233 to overcome the fungistatic or fungicidal effects of all known antifungal classes (See
234 Supplementary materials - Table 2) (Kaur et al., 2021; Vandeputte et al., 2012). Although
235 they are diverse, they fit in the following generic classes: (i) reduction of the accumulation
236 of the drug within the fungal cell; (ii) decreasing in the affinity of the drug for its target,
237 and (iii) modifications of metabolism to counterbalance the drug effect (Vandeputte et
238 al., 2012).

239 The direct consequence of the arising of resistant strains is the failure of
240 conventional antifungal treatments and the difficulty in achieving the total cure of the
241 disease (Rai et al., 2017). As such, the necessity for new antifungal agents is a reality.

242 **3. Plant extracts and essential oils as antifungal agents**

243

244 Humanity has been using plants for centuries as food source, raw materials for
245 cloth production, shelter, decoration and remedies (Veiga et al., 2020). The use of
246 medicinal plants is one of the oldest forms of healthcare known to man being a part of
247 traditional and modern medicines (Massiha and Muradov, 2015; Veiga et al., 2020).
248 Currently, in some countries of Africa, Asia and Latin America, traditional plant-based
249 medicine is still used in primary healthcare needs (Massiha and Muradov, 2015).
250 Recently, the interest of scientific community in PEs and EOs has increased because of
251 their multiple properties, including antimicrobial and antioxidant activities (Freitas and
252 Cattelan, 2018).

253 PEs are obtained by natural plants and have antioxidant activity, antimicrobial and
254 immune response mediator activities, thus being of paramount importance for human
255 health (Bashir et al., 2018; Liu et al., 2021). Besides, PEs can be effective at low
256 concentrations, are cost-effective and easy to apply and present low toxicity levels and
257 high stability during processing (Liu et al., 2021). The antifungal activity of some PEs

258 against some *Candida* and *Malassezia* species has already been determined by some
259 authors (Table 4).

260 In yeast cells, PEs provoke changes in the cell morphology, such as elongation of
261 the conidia, deposition of flocculated material in the fungal colonies and depressions on
262 the cell surface (Cavalcanti Filho et al., 2017). They are also able to disrupt the plasma
263 membrane by binding to ergosterol (Butassi et al., 2019), thus causing loss of membrane
264 integrity, leakage of cellular materials (Alyousef, 2021) and cytolysis (Okla et al., 2021).
265 Other mechanism of action of PEs is the rupture and shrinkage of fungal hyphae (Okla et
266 al., 2021). In yeasts cells, PEs exert effects on the morphogenetic transition, leading to a
267 predominance of isolated cells over budding cells and pseudohyphae (Cavalcanti Filho et
268 al., 2017). They also have an inhibitory effect on biofilm formation (Chevalier et al.,
269 2012; Ourabah et al., 2020; Soliman et al., 2017).

270 EOs are natural complex compounds composed of terpenes, aromatics and
271 terpenoid molecules (Zuzarte et al., 2011). Usually, they are characterized by two or three
272 major components, comprising 20-70% of their constitution that are responsible for most
273 of their biological activities (Donato et al., 2020). EOs are liquid at room temperature,
274 volatile, limpid, rarely colored, soluble in lipids and organic solvents, present a strong
275 odor and are usually less dense than water (Bakkali et al., 2008). More than 17500 plant
276 species are able to produce EOs that can be synthesized by all organs, and stocked in
277 different structures, like secretory cells, cavities, canals, epidermic cells, and glandular
278 trichomes (Bakkali et al., 2008; Baptista-Silva et al., 2020). EOs composition presents
279 high variability among plant species and within the same species is frequent to find EOs
280 with different chemo-types (Baptista-Silva et al., 2020). Inside the plant, EOs present a
281 protective function because they act as antimicrobials, insecticides and protect them
282 against herbivores by reducing the appetite of these animals for them. Additionally, they
283 may also attract some pollinizing insects and repel the undesirable ones (Bakkali et al.,
284 2008). They present antimicrobial activity against several microorganisms including
285 antifungal activity against *Candida* spp. and *Malassezia* spp. (Table 4).

286 Some mechanisms of action of EOs include the reduction in ergosterol content by
287 impairment of its biosynthesis (Pinto et al., 2006), damage of the cell membrane and cell
288 wall as well as lysis of the mycelia (Inouye et al., 2007), destruction of the inner
289 mitochondrial membranes and cell wall as well as expansion of endoplasmic reticulum
290 near cell membranes (Park et al., 2007), inhibition of the ion transport process (Rivera-
291 Yañez et al., 2017), intercalation between the fatty acids of lipid bilayer of the membrane

292 thus disrupting its fluidity and permeability (Rhimi et al., 2021), inhibition of the
293 respiration process (Rivera-Yañez et al., 2017) and inhibitory action on spores
294 germination (Bajpai et al., 2009). The antimicrobial activity of EOs is not attributable to
295 one specific mechanism since they are constituted by different groups of chemical
296 compounds and depends on their chemical composition. Instead, EOs act on several
297 targets and provoke a cascade of reactions that involve the entire microbial cell (Burt,
298 2004; Nazzaro et al., 2013). Overall, studies on EOs and PEs seem to indicate that the
299 antimicrobial activity of these compounds result from the effect of different substances
300 on several cell targets (Zuzarte et al., 2011). Thus, the occurrence of resistant microbes
301 to these substances seems unlikely because it would be necessary the occurrence of
302 several mutations simultaneously to overcome all the distinct mechanisms of action at
303 once (Zuzarte et al., 2011). Both EOs and PEs have a pleasant aroma which can be an
304 advantage of these compounds when compared to traditional antifungal agents.

305
306

307 **4. Films and hydrogels incorporated with PEs/EOs for the** 308 **treatment of skin yeast infections**

309

310 EOs and PEs have antifungal activity against yeasts of the genera *Candida* and
311 *Malassezia* and other important bioactive properties, such as antioxidant activity, anti-
312 inflammatory, anti-hemolytic, thrombolytic activity, anti-tumoral activity, etc. (Howard
313 et al., 2015; Kar et al., 2018; Nascimento et al., 2020; UdDen and Shahid, 2017; Xavier
314 et al., 2021). However, EOs and PEs activities can be altered due to environmental stress,
315 high temperatures that can cause epimerization, and oxygen exposure (Dai and Mumper,
316 2010; Kaur et al., 2021). Additionally, some fungal species produce enzymes that can
317 oxidize and inactivate EOs (Kaur et al., 2021). PEs and EOs also lack in targeting capacity
318 and have poor bioavailability, which limits their therapeutic efficiency (Yang et al.,
319 2018). Their incorporation in formulations such as films and hydrogels increase their
320 physical stability and may modulate their bioactivity and antimicrobial potential. It also
321 reduces the volatility and toxicity of EOs and controls their release (Bal-Öztürk et al.,
322 2021).

323

324 **4.1. Films**

325

326 Films are thin and flexible structures with a continuous matrix that can be made
327 of proteins, polysaccharides and/or lipids (Avila-Sosa et al., 2016; Karki et al., 2016).
328 The three main components of a film are polymer(s), solvent, and plasticizer, which can
329 be or not present (Avila-Sosa et al., 2016; Karki et al., 2016).

330 Polymers are the major film components; they are usually biocompatible and non-
331 toxic. Also, their mechanical and barrier properties to water, oxygen, CO₂ transference
332 and solute movements make them suitable for biomedical applications (Augusto et al.,
333 2018; Karki et al., 2016). Proteins and polysaccharides are the most common used
334 polymers in film production (Avila-Sosa et al., 2016). Water is the most used solvent to
335 obtain solutions, but in some cases, ethanol or acidic solutions can be used to dissolve the
336 polymer (Avila-Sosa et al., 2016). Solvents used in film formation need to be safe and
337 suitable for biomedical applications.

338 Plasticizing agents are used in film formation to emulsify phases that are not
339 miscible, affecting the film flexibility and resistance. Additionally, these substances make
340 the film structure smoother by increasing the mobility of the polymer chains, reducing
341 the intermolecular forces and improving mechanical properties such as elongation. The
342 most used plasticizing agents are sorbitol, glycerol, mannitol, sucrose and polyethylene
343 glycol (Avila-Sosa et al., 2016).

344 Usually, films are produced by solvent casting technique because it is feasible and
345 cost-effective (Castro, 2018). However, hot melt extrusion and printing techniques can
346 also be used (Karki et al., 2016).

347 When a film is completely formed, it needs to be characterized to understand their
348 mechanical and permeability properties but also potential functional properties. There are
349 several tests that can be performed to assess the quality parameters of a film and a
350 summary of these attributes and the methods used for its evaluation can be found on
351 Supplementary Table 3.

352 The use of films for bioactives delivery offers some advantages when compared
353 to other formulations, such as: a) non-invasive way for administration; b) easy to
354 manufacture and transport; c) cheap formulations; d) their ability to cover large body
355 areas; e) high bio-adhesion; f) uniform surface and g) transparency that permits the
356 control of skin healing without frequent changes (Karki et al., 2016; Leyva-Gómez et al.,
357 2021). An ideal film must have good drug loading capacity, fast dissolution rate or long

358 residence time at the administration site and good stability. Additionally, it should be non-
359 toxic, biocompatible and biodegradable (Karki et al., 2016).

360 EOs and PEs can be incorporated in the film matrix either by emulsification or
361 homogenization techniques, thus changing its functionality (Atarés and Chiralt, 2016;
362 Augusto et al., 2018).

363 **4.1.1. Antifungal activity of films incorporated with EOs against skin yeasts**

364

365 Nowadays, the available treatments for the management of skin infections caused
366 by yeasts are largely based on small molecule antifungal drugs. But, these substances
367 present poor solubility and bioavailability, limiting their efficiency, as well as
368 undesirable side effects, and a rise in the number of resistant yeast strains that contribute
369 for the search of new substitutes (Ntow-Boahene et al., 2021). Because of their
370 antioxidant and antifungal properties, EOs and PEs can potentially be an alternative to
371 common antifungal drugs. Additionally, their biocompatibility facilitates their
372 incorporation into polymeric materials (Ntow-Boahene et al., 2021). In fact, several
373 studies suggest that polymeric films incorporated with EOs and PEs, due to their
374 antifungal activity, can be applied to food packaging for the control of food spoilage fungi
375 (Nguyen Van Long et al., 2016). The use of films with EOs and PEs for the control of
376 skin yeast infections is still not fully understood. However, there are some studies that
377 suggest that these formulations can play a role in the control of skin candidiasis (Table
378 5). Usually, the antimicrobial activity of the films is determined by disc diffusion assay,
379 in which the film is placed on the top of the solid culture medium on Petri dishes,
380 inoculated with the bacteria; after incubation, the inhibition halo around the film is
381 measured.

382 The incorporation of EOs and PEs on films is advantageous because the
383 polymer(s) that compose the film have the ability to improve the interactions between the
384 EOs/ PEs and the fungal cell since they are electrostatically attracted to the fungal
385 membranes; polymeric films also allow a slow release of EOs over time by creating a
386 diffusion matrix and therefore increase the stability of EOs and PEs (Ntow-Boahene et
387 al., 2021). Up to date, to best of our knowledge, there are no studies, either *in vivo* or *in*
388 *vitro* (in skin cells) reporting the effect of films with PEs and EOs for the treatment of
389 *Candida* infections and, as such, additional studies in this area are needed for these
390 formulations to constitute a real alternative to the current treatments.

391 Regarding the use of polymeric films with EOs and PEs for the treatment of
392 infections caused by *Malassezia* spp. so far, to best of our knowledge, there are no studies
393 addressing the use so this review intends to tackle this hypothesis, since they have been
394 used to control *Candida* spp. infections.

395

396 **4.2. Hydrogels**

397

398 Hydrogels (HGs) are three dimension cross-linked polymeric networks, that are able to
399 absorb and retain large amounts of water by swelling up (without dissolving) (Kaur et al.,
400 2021; Micale et al., 2020). These characteristics are due to capillary, osmotic and
401 hydration forces that account for the collaboration between the polymeric chain and
402 organic liquids, contributing for the chain's network balance and expansion (Kaur et al.,
403 2021). These formulations have an excellent biocompatibility and, because of their
404 rubber-like appearance, they closely resemble living tissues, which makes them very
405 effective drug delivery systems (Das et al., 2016; Kaur et al., 2021). Because they are
406 highly porous matrices, they can be loaded and assure the prolonged release of highly
407 active compounds (Kaur et al., 2021). To boost their bio-stability and mechanical
408 strength, these scaffolds must be optimized because they do not exhibit great stability and
409 must be replaced frequently (Das et al., 2016).

410 HGs are formed by cross-linking techniques that can be physical, chemical,
411 enzymatic or irradiated, and are classified according to their synthesis method
412 (Supplementary Figure 1). The cross-linking method used in the production of a HG
413 determines its physicochemical and mechanical properties (Pan et al., 2021) with
414 different advantages and disadvantages (Supplementary Table 4). The type of polymer,
415 the cell encapsulation strategy, the drug release kinetics and the target tissue are
416 determinant for the choice of the cross-linking method to be used (Ermis et al., 2018).

417 The parameters that are used to characterize HGs are the same as those used to
418 characterize films (Supplementary Table 3).

419 Some HGs are sensitive to stimuli and respond by changing their form or volume.
420 They can respond to physical (light, pressure, temperature, electric field, magnetic field
421 and ultrasound), chemical (pH, redox, ionic strength, CO₂ and glucose) and biological
422 factors (enzymes, antigens, glutathione and DNA) (Kaur et al., 2021).

423 **4.2.1. Antifungal activity of HGs incorporated with EOs and PEs against skin**
424 **yeasts**

425

426 HGs are very effective drug delivery systems. Their properties allow them to
427 penetrate all the three layers of the skin and reach the dermis (Kaur et al., 2021), where
428 they facilitate the controlled and sustained release of the antifungal medication, thereby
429 diminishing the risk of local toxicity and excessive systemic drug levels (Zagórska-Dziok
430 and Sobczak, 2020). Furthermore, HGs have the capacity to enhance the bioavailability,
431 solubility, chemical stability, and skin penetration of drugs, ensuring the delivery of an
432 effective therapeutic dose of the antifungal agent and its retention in specific skin layers.
433 (Zagórska-Dziok and Sobczak, 2020).

434 The mechanism of action of a HG with antifungal activity involves several steps:
435 1) the swollen HG contacts with the infected skin and releases the antifungal agent,
436 mainly due to changes in pH caused by fungal growth; 2) the antifungal agent acts on the
437 fungal cell and inhibits the respiration of the cell leading to its death; or 3) the antifungal
438 inhibits the synthesis of ergosterol, causing cell death (Kaur et al., 2021). Antifungal
439 drugs in HGs are released through three different mechanisms: (a) diffusion-controlled
440 mechanism in which the gel contacts with the skin with a higher temperature than normal,
441 which leads to an increase in its hydrophobicity resulting in a slow and controlled release
442 of the antifungal substance across the concentration gradient; (b) a chemical-controlled
443 mechanism that involves reactions within the HG matrix that may be enzymatic,
444 hydrolytic, reversible, or irreversible; and (c) a swelling-controlled mechanism. The
445 specific mechanism at play depends on the type, concentration, and water-attracting
446 properties of the polymer used in the HG (Kaur et al., 2021).

447 There are some studies that demonstrate the antifungal activity of HGs with EOs
448 in the management of *Candida* sp. infections (Table 6). Usually, the antifungal activity
449 of HGs is determined by diffusion method, and the yeast that is commonly tested is *C.*
450 *albicans* due to its clinical importance. The use of HGs incorporated with PEs for the
451 treatment of skin candidiasis is also mentioned in the literature. Although less studied
452 than HGs incorporated with EOs, these formulations also have the potential to eradicate
453 *Candida* spp. In fact, (Iraqi et al., 2019) describe the preparation of a HG incorporated
454 with an extract from the plant *Cassia alata*. The formulation made of carbapol 934 and
455 propylene glycol was incorporated with the extract and showed antifungal activity against
456 *C. albicans*, both *in vitro* (in an agar diffusion test that showed the existence of an

457 inhibition halo in a *C. albicans* culture treated with the HG; the HG presented a larger
458 inhibition halo when compared to commercial formulations against the same
459 microorganism) and *in vivo* (in rat model in which the HG with PE displayed better and
460 faster healing activity than commercial formulations).

461 Regarding the treatment of infections caused by *Malassezia* spp., Mirzaii et al.
462 (2021) developed HGs incorporated with EOs of black cumin, cinnamon and orange and
463 assessed their antifungal activities against the species *M. furfur*. The antifungal activity
464 against this yeast was also tested by Dhamane et al. (2015) for a gel with tea tree oil, with
465 both authors concluding that their formulations presented antifungal activity against *M.*
466 *furfur*. Dhamane et al. (2015) also tested their hydrogel on a rat model to evaluate if was
467 irritant to the skin and concluded that it was not. Kulkarni et al. (2020) produced a sodium
468 alginate gel incorporated with the fenugreek leaves extract to test against the yeast *M.*
469 *furfur* and concluded that it had antifungal activity against this microorganism.

470 To the best of our knowledge, only these studies point to the use of HGs
471 incorporated with EOs and PEs for the treatment of *Malassezia* infections, emphasizing
472 the need of more studies in this area. Nevertheless, these formulations show promising
473 results and can potentially constitute an alternative to traditional treatments for
474 *Malassezia* sp. infections.

475

476 **5. Conclusions and future perspectives**

477

478 Skin yeast infections caused by *Candida* sp. and *Malassezia* sp., are an emerging
479 concern affecting millions of people every day. The current conventional treatments for
480 these diseases normally consist in the application of gels, ointments and creams that have
481 several undesirable side effects.

482 In this paper, the use of films and HGs for the delivery of EOs and PEs to the skin
483 aiming the treatment of mucocutaneous candidiasis and *Malassezia* caused diseases was
484 discussed.

485 The antimicrobial activity of EOs and PEs against *Candida* spp. and *Malassezia*
486 spp. is documented by several works and some studies also show that EOs and PEs
487 incorporated into films and HGs have antifungal activity against *Candida* sp., thus being
488 a possible treatment for mucocutaneous candidiasis. But more *in vivo* studies are needed
489 to assess the potential of these formulations.

490 Regarding the incorporation of these compounds in films and HGs for the
491 treatment of *Malassezia* caused diseases, the number of studies is scant. Nevertheless, the
492 authors believe that these formulations can constitute a possible treatment for these skin
493 conditions and be deeper explored in future.

494

495 **CRedit authorship contribution statement:** Ana I. Lopes: conceptualization,
496 investigation, writing - original draft, writing - review and editing; Maria M. Pintado:
497 conceptualization, writing - review and editing; Freni K. Tavaría: conceptualization,
498 writing - review and editing. All authors have read and agreed to the published version of
499 the manuscript.

500

501 **Declaration of competing interest:** The authors declare that they have no known
502 competing financial interests or personal relationships that could have appeared to
503 influence the work reported in this paper.

504

505 **Acknowledgments:** This work was supported by National Funds from FCT- Fundação
506 para a Ciência e a Tecnologia through project UIDB/50016/2020. Author Ana I. Lopes
507 would also like to acknowledge FCT for her PhD grant with the reference
508 2023.01154.BD. All figures were created with BioRender.com.

509 **References**

510

511 Aldawsari, H., Badr-Eldin, S.M., Labib, G.S., El-kamel, A.H., 2015. Design and
512 formulation of a topical hydrogel integrating lemongrass-loaded nanospheres with
513 an enhanced antifungal effect: In vitro/ in vivo evaluation. *Int. J. Nanomedicine* 10,
514 893–902. <https://doi.org/10.2147/IJN.S74771>

515 Almeida, C.M. de, Rocha, E.A.L. de S.S., Alves, É.P., Lima, R. de, Freitas, Cavalcanti,
516 Y.W., Gomes, R.C.B., Pereira, J.V., Costa, E.M., Brito, M. de, 2019. In vitro
517 Evaluation of the Antimicrobial Potential of *Salvia officinalis* L. against Oral
518 Pathogens. *J. Heal. Sci.* 21, 129–133. [https://doi.org/10.17921/2447-](https://doi.org/10.17921/2447-8938.2019v21n2p129-133)
519 8938.2019v21n2p129-133

520 Alyousef, A.A., 2021. Antifungal Activity and Mechanism of Action of Different Parts
521 of *Myrtus communis* Growing in Saudi Arabia against *Candida* Spp. *J. Nanomater.*

522 2021, 3484125. <https://doi.org/10.1155/2021/3484125>

523 Angiolella, L., Carradori, S., Maccallini, C., Giusiano, G., Supuran, C., 2017a.

524 Targeting *Malassezia* species for Novel Synthetic and Natural Antidandruff

525 Agents. *Curr. Med. Chem.* 24, 2392–2412.

526 <https://doi.org/10.2174/0929867324666170404110631>

527 Angiolella, L., Leone, C., Rojas, F., Mussin, J., Sosa, M. de los Á., Giusiano, G., 2017b.

528 Biofilm, adherence, and hydrophobicity as virulence factors in *Malassezia furfur*.

529 *Med. Mycol.* 56, 110–116. <https://doi.org/10.1093/mmy/myx014>

530 Arikan, S., Ostrosky-Zeichner, L., Lozano-Chiu, M., Paetznick, V., Gordon, D.,

531 Wallace, T., Rex, J.H., 2002. In Vitro Activity of Nystatin Compared with Those

532 of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical *Candida*

533 Isolates. *J. Clin. Microbiol.* 40, 1406–1412. [https://doi.org/10.1128/jcm.40.4.1406-](https://doi.org/10.1128/jcm.40.4.1406-1412.2002)

534 [1412.2002](https://doi.org/10.1128/jcm.40.4.1406-1412.2002)

535 Atarés, L., Chiralt, A., 2016. Essential oils as additives in biodegradable films and

536 coatings for active food packaging. *Trends Food Sci. Technol.* 48, 51–62.

537 <https://doi.org/https://doi.org/10.1016/j.tifs.2015.12.001>

538 Augusto, A., Dias, J.R., Campos, M.J., Alves, N.M., Pedrosa, R., Silva, S.F.J., 2018.

539 Influence of *Codium tomentosum* Extract in the Properties of Alginate and

540 Chitosan Edible Films. *Foods* 7, 53. <https://doi.org/10.3390/foods7040053>

541 Avila-Sosa, R., Palou, E., López-Malo, A., 2016. Chapter 15 - Essential Oils Added to

542 Edible Films, *Essential Oils in Food Preservation, Flavor and Safety*. Academic

543 Press, San Diego. [https://doi.org/https://doi.org/10.1016/B978-0-12-416641-](https://doi.org/https://doi.org/10.1016/B978-0-12-416641-7.00015-8)

544 [7.00015-8](https://doi.org/https://doi.org/10.1016/B978-0-12-416641-7.00015-8)

545 Bajpai, V.K., Yoon, J.I., Kang, S.C., 2009. Antifungal potential of essential oil and

546 various organic extracts of *Nandina domestica* Thunb. against skin infectious

547 fungal pathogens. *Appl. Microbiol. Biotechnol.* 83, 1127–1133.

548 <https://doi.org/10.1007/s00253-009-2017-5>

549 Bakkali, F., Averbeck, S., Averbeck, D., Idaomar, M., 2008. Biological effects of

550 essential oils - A review. *Food Chem. Toxicol.* 46, 446–475.

551 <https://doi.org/10.1016/j.fct.2007.09.106>

552 Bal-Öztürk, A., Özkahraman, B., Özbaş, Z., Yaşayan, G., Tamahkar, E., Alarçin, E.,

553 2021. Advancements and future directions in the antibacterial wound dressings – A

554 review. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 109B, 703–716.

555 <https://doi.org/https://doi.org/10.1002/jbm.b.34736>

556 Baptista-Silva, S., Borges, S., Ramos, O.L., Pintado, M., Sarmiento, B., 2020. The
557 progress of essential oils as potential therapeutic agents: a review. *J. Essent. Oil*
558 *Res.* 32, 279–295. <https://doi.org/10.1080/10412905.2020.1746698>

559 Barac, A., Donadu, M., Usai, D., Spiric, V.T., Mazzarello, V., Zanetti, S., Aleksic, E.,
560 Stevanovic, G., Nikolic, N., Rubino, S., 2018. Antifungal activity of *Myrtus*
561 *communis* against *Malassezia* sp. isolated from the skin of patients with pityriasis
562 *versicolor*. *Infection* 46, 253–257. <https://doi.org/10.1007/s15010-017-1102-4>

563 Bashir, A., Jabeen, S., Gull, N., Islam, A., Sultan, M., Ghaffar, A., Khan, S., Sagar, S.,
564 Jamil, T., 2018. Co-concentration effect of silane with natural extract on
565 biodegradable polymeric films for food packaging. *Int. J. Biol. Macromol.* 106,
566 351–359. <https://doi.org/10.1016/j.ijbiomac.2017.08.025>

567 Boccalon, E., Pica, M., Romani, A., Casciola, M., Sterflinger, K., Pietrella, D.,
568 Nocchetti, M., 2020. Facile preparation of organic-inorganic hydrogels containing
569 silver or essential oil with antimicrobial effects. *Appl. Clay Sci.* 190, 105567.
570 <https://doi.org/https://doi.org/10.1016/j.clay.2020.105567>

571 Bona, E., Cantamessa, S., Pavan, M., Novello, G., Massa, N., Rocchetti, A., Berta, G.,
572 Gamalero, E., 2016. Sensitivity of *Candida albicans* to essential oils: are they an
573 alternative to antifungal agents? *J. Appl. Microbiol.* 121, 1530--1545.
574 <https://doi.org/10.1111/jam.13282>

575 Bongomin, F., Gago, S., Oladele, R.O., Denning, D.W., 2017. Global and Multi-
576 National Prevalence of Fungal Diseases—Estimate Precision. *J. Fungi* 3.
577 <https://doi.org/10.3390/jof3040057>

578 Bonifácio, B.V., dos Santos Ramos, M.A., da Silva, P.B., Negri, K.M.S., de Oliveira
579 Lopes, É., de Souza, L.P., Vilegas, W., Pavan, F.R., Chorilli, M., Bauab, T.M.,
580 2015. Nanostructured lipid system as a strategy to improve the anti-*Candida*
581 *albicans* activity of *Astronium* sp. *Int. J. Nanomedicine* 10, 5081–5092.
582 <https://doi.org/10.2147/IJN.S79684>

583 Boxberger, M., Cenizo, V., Cassir, N., La Scola, B., 2021. Challenges in exploring and
584 manipulating the human skin microbiome. *Microbiome* 9, 125.
585 <https://doi.org/10.1186/s40168-021-01062-5>

586 Brodin, K., Alahyar, H., Hedner, T., Sterner, O., Faergemann, J., 2007. In Vitro Activity
587 of *Artemisia abrotanum* Extracts Against *Malassezia* Spp., *Candida albicans* and
588 *Staphylococcus aureus*. *Acta Derm. Venereol.* 87, 540–542.
589 <https://doi.org/10.2340/00015555-0312>

590 Brown, G., Denning, D., Gow, N., Levitz, S., Netea, M., White, T., 2012. Hidden
591 Killers: Human Fungal Infections. *Sci. Transl. Med.* 4, 165rv13.
592 <https://doi.org/10.1126/scitranslmed.3004404>

593 Burt, S., 2004. Essential oils: their antibacterial properties and potential applications in
594 foods—a review. *Int. J. Food Microbiol.* 94, 223–253.
595 <https://doi.org/https://doi.org/10.1016/j.ijfoodmicro.2004.03.022>

596 Butassi, E., Svetaz, L.A., Zhou, S., Wolfender, J.-L., Cortés, J.C.G., Ribas, J.C., Díaz,
597 C., Palacio, J.P., Vicente, F., Zacchino, S.A., 2019. The antifungal activity and
598 mechanisms of action of quantified extracts from berries, leaves and roots of
599 *Phytolacca tetramera*. *Phytomedicine* 60, 152884.
600 <https://doi.org/https://doi.org/10.1016/j.phymed.2019.152884>

601 Byrd, A.L., Belkaid, Y., Segre, J.A., 2018. The human skin microbiome. *Nat. Rev.*
602 *Microbiol.* 16, 143–155. <https://doi.org/10.1038/nrmicro.2017.157>

603 Cafarchia, C., Iatta, R., Immediato, D., Puttilli, M., Otranto, D., 2015. Azole
604 susceptibility of *Malassezia pachydermatis* and *Malassezia furfur* and tentative
605 epidemiological cut-off values. *Med. Mycol.* 53, 743–748.
606 <https://doi.org/10.1093/mmy/myv049>

607 Carbone, C., Teixeira, M. do C., Sousa, M. do C., Martins-Gomes, C., Silva, A.M.,
608 Souto, E.M.B., Musumeci, T., 2019. Clotrimazole-Loaded Mediterranean Essential
609 Oils NLC: A Synergic Treatment of *Candida* Skin Infections. *Pharmaceutics* 11,
610 231. <https://doi.org/10.3390/pharmaceutics11050231>

611 Castro, P.J.N.M. de, 2018. Association of micro and nanocarriers with thin films for
612 buccal delivery of bioactive molecules. Universidade Católica Portuguesa - Porto.

613 Cavalcanti Filho, J.R.N., Silva, T.F., Nobre, W.Q., Oliveira de Souza, L.I., Silva e Silva
614 Figueiredo, C.S., Figueiredo, R.C.B.Q. de, de Gusmão, N.B., Silva, M.V.,
615 Nascimento da Silva, L.C., Correia, M.T. dos S., 2017. Antimicrobial activity of
616 *Buchenavia tetraphylla* against *Candida albicans* strains isolated from vaginal
617 secretions. *Pharm. Biol.* 55, 1521–1527.
618 <https://doi.org/10.1080/13880209.2017.1304427>

619 Chandra, S., Srinivas, R., Dawson, T., Common, J., 2021. Cutaneous *Malassezia*:
620 Commensal, Pathogen, or Protector? *Front. Cell. Infect. Microbiol.* 10, 614446.
621 <https://doi.org/10.3389/fcimb.2020.614446>

622 Chen, M., Zhai, L., Arendrup, M.C., 2015. In vitro activity of 23 tea extractions and
623 epigallocatechin gallate against *Candida* species. *Med. Mycol.* 53, 194–198.

624 <https://doi.org/10.1093/mmy/myu073>

625 Chevalier, M., Medioni, E., Prêcheur, I., 2012. Inhibition of *Candida albicans* yeast–
626 hyphal transition and biofilm formation by *Solidago virgaurea* water extracts. *J.*
627 *Med. Microbiol.* 61, 1016–1022. <https://doi.org/10.1099/jmm.0.041699-0>

628 Cook, J.P., Goodall, G.W., Khutoryanskaya, O. V, Khutoryanskiy, V. V, 2012.
629 Microwave-Assisted Hydrogel Synthesis: A New Method for Crosslinking
630 Polymers in Aqueous Solutions. *Macromol. Rapid Commun.* 33, 332–336.
631 <https://doi.org/https://doi.org/10.1002/marc.201100742>

632 Dai, J., Mumper, R., 2010. Plant Phenolics: Extraction, Analysis and Their Antioxidant
633 and Anticancer Properties. *Molecules* 15, 7313–7352.
634 <https://doi.org/10.3390/molecules15107313>

635 Das, U., Behera, S.S., Singh, S., Rizvi, S.I., Singh, A.K., 2016. Progress in the
636 Development and Applicability of Potential Medicinal Plant Extract-Conjugated
637 Polymeric Constructs for Wound Healing and Tissue Regeneration. *Phyther. Res.*
638 30, 1895–1904. <https://doi.org/https://doi.org/10.1002/ptr.5700>

639 De-Oliveira, A.P.-, De-Oliveira, R.P.-, Gaspar, C., Salgueiro, L., Cavaleiro, C., De-
640 Oliveira, J.M.-, Queiroz, J.A., Rodrigues, A.G., 2013. Association of *Thymbra*
641 *capitata* essential oil and chitosan (TCCH hydrogel): a putative therapeutic tool for
642 the treatment of vulvovaginal candidosis. *Flavour Fragr. J.* 28, 354–359.
643 <https://doi.org/https://doi.org/10.1002/ffj.3144>

644 de Abreu, L.C.L., Todaro, V., Sathler, P.C., da Silva, L.C.R.P., do Carmo, F.A., Costa,
645 C.M., Toma, H.K., Castro, H.C., Rodrigues, C.R., de Sousa, V.P., Cabral, L.M.,
646 2016. Development and Characterization of Nisin Nanoparticles as Potential
647 Alternative for the Recurrent Vaginal Candidiasis Treatment. *AAPS*
648 *PharmSciTech* 17, 1421–1427. <https://doi.org/10.1208/s12249-016-0477-3>

649 de Paula, G.A., Costa, N.N., da Silva, T.M., Bastos, K.A., Ignacchiti, M.D.C., Severi,
650 J.A., Oréface, R.L., Carreira, L.G., Villanova, J.C.O., Resende, J.A., 2022.
651 Polymeric film containing pomegranate peel extract as a promising tool for the
652 treatment of candidiasis. *Nat. Prod. Res.* 1–5.
653 <https://doi.org/10.1080/14786419.2022.2064464>

654 Dhamane, S.P., Tayade, N., Potnis, V.V., Kulkarni, A.S., Gadekar, A.S., 2015.
655 Formulation and evaluation of antidandruff hair gel for treatment of seborrhoeic
656 dermatitis. *World J. Pharm. Res.* 4, 1260–1271.

657 Dinu, M.V., Gradinaru, A.C., Lazar, M.M., Dinu, I.A., Raschip, I.E., Ciocarlan, N.,

658 Aprotosoai, A.C., 2021. Physically cross-linked chitosan/dextrin cryogels
659 entrapping *Thymus vulgaris* essential oil with enhanced mechanical, antioxidant
660 and antifungal properties. *Int. J. Biol. Macromol.* 184, 898–908.
661 <https://doi.org/https://doi.org/10.1016/j.ijbiomac.2021.06.068>

662 Dispenza, C., Giacomazza, D., Jonsson, M., 2021. Micro- to Nanoscale Bio-Hybrid
663 Hydrogels Engineered by Ionizing Radiation. *Biomolecules* 11, 47.
664 <https://doi.org/10.3390/biom11010047>

665 Donato, R., Sacco, C., Pini, G., Bilia, A.R., 2020. Antifungal activity of different
666 essential oils against *Malassezia* pathogenic species. *J. Ethnopharmacol.* 249,
667 112376. <https://doi.org/https://doi.org/10.1016/j.jep.2019.112376>

668 English, J.S.C., Dawe, R.S., Ferguson, J., 2003. Environmental effects and skin disease.
669 *Br. Med. Bull.* 68, 129–142. <https://doi.org/10.1093/bmb/ldg026>

670 Ermis, M., Calamak, S., Calibasi Kocal, G., Guven, S., Durmus, N.G., Rizvi, I., Hasan,
671 T., Hasirci, N., Hasirci, V., Demirci, U., 2018. Chapter 15 - Hydrogels as a New
672 Platform to Recapitulate the Tumor Microenvironment, in: Conde, J.B.T.-H. of N.
673 for C.T. (Ed.), *Handbook of Nanomaterials for Cancer Theranostics*. Elsevier, pp.
674 463–494. <https://doi.org/https://doi.org/10.1016/B978-0-12-813339-2.00015-3>

675 Fernandes, A., Rodrigues, P.M., Pintado, M., Tavora, F.K., 2023. A systematic review
676 of natural products for skin applications: Targeting inflammation, wound healing,
677 and photo-aging. *Phytomedicine* 115, 154824.
678 <https://doi.org/https://doi.org/10.1016/j.phymed.2023.154824>

679 Figueredo, L., Cafarchia, C., Otranto, D., 2013. Antifungal susceptibility of *Malassezia*
680 *pachydermatis* biofilm. *Med. Mycol.* 51, 863–867.
681 <https://doi.org/10.3109/13693786.2013.805440>

682 Fournière, M., Latire, T., Souak, D., Feuilloley, M.G.J., Bedoux, G., 2020.
683 *Staphylococcus epidermidis* and *Cutibacterium acnes*: Two Major Sentinels of
684 Skin Microbiota and the Influence of Cosmetics. *Microorganisms*.
685 <https://doi.org/10.3390/microorganisms8111752>

686 Freitas, I.R., Cattelan, M.G., 2018. Chapter 15 - Antimicrobial and Antioxidant
687 Properties of Essential Oils in Food Systems—An Overview, in: Holban, A.M.,
688 Grumezescu, A.M.B.T.-M.C. and F.D. (Eds.), *Handbook of Food Bioengineering:*
689 *Volume 10: Microbial Contamination and Food Degradation*. Academic Press, pp.
690 443–470. <https://doi.org/https://doi.org/10.1016/B978-0-12-811515-2.00015-9>

691 Grice, E.A., Segre, J.A., 2011. The skin microbiome. *Nat. Rev. Microbiol.* 9, 244–253.

692 <https://doi.org/10.1038/nrmicro2537>

693 Gupta, M., Agrawal, U., Vyas, S., 2012. Nanocarrier-based topical drug delivery for the
694 treatment of skin diseases. *Expert Opin. Drug Deliv.* 9, 783–804.
695 <https://doi.org/10.1517/17425247.2012.686490>

696 Hafsa, J., Smach, M. ali, Ben Khedher, M.R., Charfeddine, B., Limem, K., Majdoub,
697 H., Rouatbi, S., 2016. Physical, antioxidant and antimicrobial properties of
698 chitosan films containing *Eucalyptus globulus* essential oil. *LWT - Food Sci.*
699 *Technol.* 68, 356–364. <https://doi.org/10.1016/j.lwt.2015.12.050>

700 Hammer, K.A., Carson, C.F., Riley, T. V., 2000. In Vitro Activities of Ketoconazole,
701 Econazole, Miconazole, and *Melaleuca alternifolia* (Tea Tree) Oil against
702 *Malassezia* Species. *Antimicrob. Agents Chemother.* 44, 467–469.
703 <https://doi.org/10.1128/AAC.44.2.467-469.2000>

704 Hannigan, G.D., Grice, E.A., 2013. Microbial Ecology of the Skin in the Era of
705 Metagenomics and Molecular Microbiology. *Cold Spring Harb. Perspect. Med.* 3,
706 a015362–a015362. <https://doi.org/10.1101/cshperspect.a015362>

707 Hay, R., 2018. Therapy of Skin, Hair and Nail Fungal Infections. *J. Fungi* 4, 99.
708 <https://doi.org/10.3390/jof4030099>

709 Hennink, W.E., van Nostrum, C.F., 2002. Novel crosslinking methods to design
710 hydrogels. *Adv. Drug Deliv. Rev.* 54, 13–36.
711 [https://doi.org/10.1016/S0169-409X\(01\)00240-X](https://doi.org/10.1016/S0169-409X(01)00240-X)

712 Höfling, José Francisco Puppim, D. de G.P.B., Anibal, P.C., de Feiria, S.N.B., de
713 Oliveira, Thaís Rossini Boni, G.C., Barbosa, Janaína Priscila Teixeira, Anderson
714 Laerte Sardi, J. de C.O., Rosalen, P.L., 2019. Susceptibility Profile of the Essential
715 Oil from *E. muticus* against *C. albicans* Biofilm. *EC Dent. Sci.* 18, 1844–1857.

716 Hort, W., Mayser, P., 2010. *Malassezia* virulence determinants. *Curr. Opin. Infect. Dis.*
717 24, 100–105. <https://doi.org/10.1097/QCO.0b013e328342f787>

718 Howard, C.B., Johnson, W.K., Pervin, S., Izevbigie, E.B., 2015. Recent perspectives on
719 the anticancer properties of aqueous extracts of Nigerian *Vernonia amygdalina*.
720 *Bot. Targets Ther.* 5, 65. <https://doi.org/10.2147/BTAT.S62984>

721 Hu, W., Wang, Z., Xiao, Y., Zhang, S., Wang, J., 2019. Advances in crosslinking
722 strategies of biomedical hydrogels. *Biomater. Sci.* 7, 843–855.
723 <https://doi.org/10.1039/C8BM01246F>

724 Inouye, S., Nishiyama, Y., Uchida, K., Hasumi, Y., Yamaguchi, H., Abe, S., 2007. The
725 vapor activity of oregano, perilla, tea tree, lavender, clove, and geranium oils

726 against a Trichophyton mentagrophytes in a closed box. *J. Infect. Chemother.* 12,
727 349–354. <https://doi.org/10.1007/s10156-006-0474-7>

728 Iraqui, P., Chakraborty, T., Das, M.K., Yadav, R.N.S., 2019. Herbal antimicrobial gel
729 with leaf extract of *Cassia alata* L. *J. Drug Deliv. Ther.* 9, 82–94.
730 <https://doi.org/10.22270/jddt.v9i3.2527>

731 Kar, S., Gupta, P., Gupta, J., 2018. Essential Oils: Biological Activity Beyond
732 Aromatherapy. *Nat. Prod. Sci.* 24, 139–147.
733 <https://doi.org/10.20307/nps.2018.24.3.139>

734 Karki, S., Kim, H., Na, S.-J., Shin, D., Jo, K., Lee, J., 2016. Thin films as an emerging
735 platform for drug delivery. *Asian J. Pharm. Sci.* 11, 559–574.
736 <https://doi.org/https://doi.org/10.1016/j.ajps.2016.05.004>

737 Kaur, N., Bains, A., Kaushik, R., Dhull, S.B., Melinda, F., Chawla, P., 2021. A Review
738 on Antifungal Efficiency of Plant Extracts Entrenched Polysaccharide-Based
739 Nanohydrogels. *Nutrients* 13, 2055. <https://doi.org/10.3390/nu13062055>

740 Khosravi, A.R., Shokri, H., Fahimirad, S., 2016. Efficacy of medicinal essential oils
741 against pathogenic *Malassezia* sp. isolates. *J. Mycol. Med.* 26, 28–34.
742 <https://doi.org/https://doi.org/10.1016/j.mycmed.2015.10.012>

743 Korukonda, J.R., Paria, S., 2016. Anti-*Malassezia furfur* Activity of Natural Surfactant
744 Mediated In-Situ Silver Nanoparticles for a Better Antidandruff Shampoo
745 Formulation. *RSC Adv.* 6, 11064–11069. <https://doi.org/10.1039/C5RA23174D>

746 Kozics, K., Bučková, M., Puškárová, A., Kalászová, V., Cabicarová, T., Pangallo, D.,
747 2019. The Effect of Ten Essential Oils on Several Cutaneous Drug-Resistant
748 Microorganisms and Their Cyto/Genotoxic and Antioxidant Properties. *Molecules*
749 24, 4570. <https://doi.org/10.3390/molecules24244570>

750 Kozłowska, J., Tylkowski, B., Stachowiak, N., Prus-Walendziak, W., 2020. Controlling
751 the Skin Barrier Quality through the Application of Polymeric Films Containing
752 Microspheres with Encapsulated Plant Extract. *Processes.*
753 <https://doi.org/10.3390/pr8050530>

754 Kulkarni, M., Hastak, V., Jadhav, V., Date, A.A., 2020. Fenugreek Leaf Extract and Its
755 Gel Formulation Show Activity Against *Malassezia furfur*. *Assay Drug Dev.*
756 *Technol.* 18, 45–55. <https://doi.org/10.1089/adt.2019.918>

757 Kumar, L., Verma, S., Bhardwaj, A., Vaidya, S., Vaidya, B., 2014. Eradication of
758 superficial fungal infections by conventional and novel approaches: A
759 comprehensive review. *Artif. Cells Blood Substitutes Biotechnol.* 42, 32–46.

760 <https://doi.org/10.3109/21691401.2013.769446>

761 Lalitha, S.G., Thimappa, L., Ramachandrappa, Krishnamurthy, S., Basavaraju, J.,
762 Thirumale, S., 2008. Insignificant antifungal activity of plant extracts on
763 *Malassezia furfur*. *J. Pharm. Negat. Results* 7, 16–20.

764 Leong, C., Buttafuoco, A., Glatz, M., Bosshard, P., 2017. Antifungal Susceptibility
765 Testing of *Malassezia* spp. with an Optimized Colorimetric Broth Microdilution
766 Method. *J. Clin. Microbiol.* 55, 1883–1893. <https://doi.org/10.1128/JCM.00338-17>

767 Leyva-Gómez, G., González Torres, M., Alcalá, S., Bernal-Chávez, S., Morales-Morfin,
768 J., del Carmen, M., Sharifi-Rad, J., Figueroa-González, G., Reyes-Hernández, O.,
769 Del Prado, M., Cortés, H., 2021. Development of films from natural sources for
770 infections during wound healing. *Cell. Mol. Biol.* 67, 96–100.
771 <https://doi.org/10.14715/cmb/2021.67.1.14>

772 Liakos, I., Rizzello, L., Scurr, D., Pompa, P., Athanassiou, A., 2014. All-Natural
773 Composite Wound Dressing Films of Essential Oils Encapsulated in Sodium
774 Alginate with Antimicrobial Properties. *Int. J. Pharm.* 463, 137–145.
775 <https://doi.org/10.1016/j.ijpharm.2013.10.046>

776 Liu, T., Liu, L., Gong, X., Chi, F., Ma, Z., 2021. Fabrication and comparison of active
777 films from chitosan incorporating different spice extracts for shelf life extension of
778 refrigerated pork. *LWT* 135, 110181.
779 <https://doi.org/https://doi.org/10.1016/j.lwt.2020.110181>

780 Low, W.L., Kenward, M.A. (Ken), Mohd Amin, M.C.I., Martin, C., 2016. Ionically
781 Crosslinked Chitosan Hydrogels for the Controlled Release of Antimicrobial
782 Essential Oils and Metal Ions for Wound Management Applications. *Medicines* 3,
783 8. <https://doi.org/10.3390/medicines3010008>

784 M, G., K, F., Gowda, D., 2020. A Review on Candidiasis resistance current drug
785 development process in its prevention and treatment. *Int. J. Res. Pharm. Sci.* 11,
786 1073–1079. <https://doi.org/10.26452/ijrps.v11i1.1938>

787 Massiha, A., Muradov, P., 2015. Comparison of Antifungal Activity of Extracts of Ten
788 Plant Species and Griseofulvin Against Human Pathogenic Dermatophytes.
789 *Zahedan J. Res. Med. Sci.* 17, 29–34. <https://doi.org/10.17795/zjrms-2096>

790 Micale, N., Citarella, A., Molonia, M.S., Speciale, A., Cimino, F., Saija, A., Cristani,
791 M., 2020. Hydrogels for the Delivery of Plant-Derived (Poly)Phenols. *Molecules*
792 25, 3254. <https://doi.org/10.3390/molecules25143254>

793 Mirzaii, M., Yaeghoobi, M., Afzali, M., Amir Khalili, N., Mahmoodi, M., Sajirani, E.B.,

794 2021. Antifungal activities of quince seed mucilage hydrogel decorated with
795 essential oils of *Nigella sativa*, *Citrus sinensis* and *Cinnamomum verum*. *Iran. J.*
796 *Microbiol.* 13, 352–359. <https://doi.org/10.18502/ijm.v13i3.6398>

797 Moreira Teixeira, L.S., Feijen, J., van Blitterswijk, C.A., Dijkstra, P.J., Karperien, M.,
798 2012. Enzyme-catalyzed crosslinkable hydrogels: Emerging strategies for tissue
799 engineering. *Biomaterials* 33, 1281–1290.
800 <https://doi.org/https://doi.org/10.1016/j.biomaterials.2011.10.067>

801 Nascimento, L.D. do, Moraes, A.A.B. de, Costa, K.S. da, Galúcio, J.M.P., Taube, P.S.,
802 Costa, C.M.L., Cruz, J.N., Andrade, E.H. de A., Faria, L.J.G. de, 2020. No
803 Bioactive Natural Compounds and Antioxidant Activity of Essential Oils from
804 Spice Plants: New Findings and Potential Applications Title. *Biomolecules* 10, 988.
805 <https://doi.org/10.3390/biom10070988>

806 Nazzaro, F., Fratianni, F., De Martino, L., Coppola, R., De Feo, V., 2013. Effect of
807 Essential Oils on Pathogenic Bacteria. *Pharmaceuticals* 6, 1451–1474.
808 <https://doi.org/10.3390/ph6121451>

809 Nguyen Van Long, N., Joly, C., Dantigny, P., 2016. Active packaging with antifungal
810 activities. *Int. J. Food Microbiol.* 220, 73–90.
811 <https://doi.org/https://doi.org/10.1016/j.ijfoodmicro.2016.01.001>

812 Ntow-Boahene, W., Cook, D., Good, L., 2021. Antifungal Polymeric Materials and
813 Nanocomposites. *Front. Bioeng. Biotechnol.* 9, 780328.
814 <https://doi.org/10.3389/fbioe.2021.780328>

815 Okla, M.K., Alatar, A.A., Al-amri, S.S., Soufan, W.H., Ahmad, A., Abdel-Maksoud,
816 M.A., 2021. Antibacterial and Antifungal Activity of the Extracts of Different
817 Parts of *Avicennia marina* (Forssk.) Vierh. *Plants* 10, 252.
818 <https://doi.org/10.3390/plants10020252>

819 Ourabah, A., Atmani-Kilani, D., Debbache-Benaida, N., Kolesova, O., Azib, L., Yous,
820 F., Benloukil, M., Botta, B., Atmani, D., Simonetti, G., 2020. Anti-*Candida*
821 *albicans* biofilm activity of extracts from two selected indigenous Algerian plants:
822 *Clematis flammula* and *Fraxinus angustifolia*. *J. Herb. Med.* 20, 100319.
823 <https://doi.org/10.1016/j.hermed.2019.100319>

824 Pan, Z., Ye, H., Wu, D., 2021. Recent advances on polymeric hydrogels as wound
825 dressings. *APL Bioeng.* 5, 11504. <https://doi.org/10.1063/5.0038364>

826 Park, M.-J., Gwak, K.-S., Yang, I., Choi, W.-S., Jo, H.-J., Chang, J.-W., Jeung, E.-B.,
827 Choi, I.-G., 2007. Antifungal activities of the essential oils in *Syzygium*

828 aromaticum (L.) Merr. Et Perry and *Leptospermum petersonii* Bailey and their
829 constituents against various Dermatophytes. *J. Microbiol.* 45, 460–465.

830 Pedrosa, A., Lisboa, C., Rodrigues, A., 2018. *Malassezia* infections with systemic
831 involvement: Figures and facts. *J. Dermatol.* 45, 1–5. [https://doi.org/10.1111/1346-](https://doi.org/10.1111/1346-8138.14653)
832 8138.14653

833 Pedrosa, A., Lisboa, C., Rodrigues, A., 2014. *Malassezia* infections: A medical
834 conundrum. *J. Am. Acad. Dermatol.* 71, 170–176.
835 <https://doi.org/10.1016/j.jaad.2013.12.022>

836 Pedroso, R. dos S., Balbino, B.L., Andrade, G., Dias, M.C.P.S., Alvarenga, T.A.,
837 Pedroso, R.C.N., Pimenta, L.P., Lucarini, R., Pauletti, P.M., Januário, A.H.,
838 Carvalho, M.T.M., Miranda, M.L.D., Pires, R.H., 2019. In Vitro and In Vivo Anti-
839 *Candida* spp. Activity of Plant-Derived Products. *Plants (Basel)* 8, 494.

840 Pelletier, R., Peter, J., Antin, C., Gonzalez, C., Wood, L., Walsh, T., 2000. Emergence
841 of Resistance of *Candida albicans* to Clotrimazole in Human Immunodeficiency
842 Virus-Infected Children: In Vitro and Clinical Correlations. *J. Clin. Microbiol.* 38,
843 1563–1568. <https://doi.org/10.1128/JCM.38.4.1563-1568.2000>

844 Pereira, S.G., Moura, J., Carvalho, E., Empadinhas, N., 2017. Microbiota of Chronic
845 Diabetic Wounds: Ecology, Impact, and Potential for Innovative Treatment
846 Strategies. *Front. Microbiol.* 8.

847 Pfaller, M.A., Bale, M., Buschelman, B., Lancaster, M., Espinel-Ingroff, A., Rex, J.H.,
848 Rinaldi, M.G., 1994. Selection of candidate quality control isolates and tentative
849 quality control ranges for in vitro susceptibility testing of yeast isolates by National
850 Committee for Clinical Laboratory Standards proposed standard methods. *J. Clin.*
851 *Microbiol.* 32, 1650–1653.

852 Pinto, E., Pina-Vaz, C., Salgueiro, L., Gonçalves, M.J., Costa-De-Oliveira, S.,
853 Cavaleiro, C., Palmeira, A., Rodrigues, A., Martinez-De-Oliveira, J., 2006.
854 Antifungal activity of the essential oil of *Thymus pulegioides* on *Candida*,
855 *Aspergillus* and dermatophyte species. *J. Med. Microbiol.* 55, 1367–1373.
856 <https://doi.org/10.1099/jmm.0.46443-0>

857 Qureshi, M.A., Khatoun, F., Rizvi, M.A., Zafaryab, M., 2015. Ethyl acetate *Salix alba*
858 leaves extract-loaded chitosan-based hydrogel film for wound dressing
859 applications. *J. Biomater. Sci. Polym. Ed.* 26, 1452–1464.
860 <https://doi.org/10.1080/09205063.2015.1100843>

861 Rai, M., Ingle, A., Pandit, R., Paralikar, P., Gupta, I., Anasane, N., Voljč, M., 2017.

862 Nanotechnology for the Treatment of Fungal Infections on Human Skin, in: The
863 Microbiology of Skin, Soft Tissue, Bone and Joint Infections. pp. 169–184.
864 <https://doi.org/10.1016/B978-0-12-811079-9.00019-7>

865 Rhimi, W., Ben Salem, I., Iatta, R., Chaabane, H., Saidi, M., Boulila, A., Cafarchia, C.,
866 2018. *Dittrichia viscosa* L. leaves lipid extract: An unexploited source of essential
867 fatty acids and tocopherols with antifungal and anti-inflammatory properties. *Ind.*
868 *Crops Prod.* 113, 196–201.
869 <https://doi.org/https://doi.org/10.1016/j.indcrop.2018.01.032>

870 Rhimi, W., Theelen, B., Boekhout, T., Aneke, C.I., Otranto, D., Cafarchia, C., 2021.
871 Conventional therapy and new antifungal drugs against *Malassezia* infections.
872 *Med. Mycol.* 59, 215–234. <https://doi.org/10.1093/mmy/myaa087>

873 Rivera-Yañez, C.R., Terrazas, L.I., Jiménez-Estrada, M., Campos, J.E., Flores-Ortiz,
874 C.M., Hernandez, L.B., Sánchez, T., Garrido-Fariña, G.I., Rodriguez-Monroy,
875 M.A., Canales-Martinez, M.M., 2017. Anti-Candida Activity of *Bursera*
876 *morelensis* Ramirez Essential Oil and Two Compounds, α -Pinene and γ -
877 Terpinene—An In Vitro Study. *Molecules* 22, 2095.
878 <https://doi.org/10.3390/molecules22122095>

879 Ro, B., Dawson, T., 2006. The Role of Sebaceous Gland Activity and Scalp Microfloral
880 Metabolism in the Etiology of Seborrheic Dermatitis and Dandruff. *J. Investig.*
881 *Dermatol. Symp. Proc.* 10, 194–197. [https://doi.org/10.1111/j.1087-](https://doi.org/10.1111/j.1087-0024.2005.10104.x)
882 [0024.2005.10104.x](https://doi.org/10.1111/j.1087-0024.2005.10104.x)

883 Roque, L., Duarte, N., Bronze, M.R., Garcia, C., Alopaeus, J., Molpeceres, J.,
884 Hagesaether, E., Tho, I., Rijo, P., Reis, C., 2018. Development of a bioadhesive
885 nanoformulation with *Glycyrrhiza glabra* L. extract against *Candida albicans*.
886 *Biofouling* 34, 880–892. <https://doi.org/10.1080/08927014.2018.1514391>

887 Santos, E.P. dos, Nicácio, P.H.M., Barbosa, F.C., Silva, H.N. da, Andrade, A.L.S.,
888 Fook, M.V.L., Silva, S.M. de, Lima, I.F.L., 2019. Chitosan/Essential Oils
889 Formulations for Potential Use as Wound Dressing: Physical and Antimicrobial
890 Properties. *Materials (Basel)*. 12, 2223. <https://doi.org/10.3390/ma12142223>

891 Saunders, C., Scheynius, A., Heitman, J., 2012. *Malassezia* Fungi Are Specialized to
892 Live on Skin and Associated with Dandruff, Eczema, and Other Skin Diseases.
893 *PLoS Pathog.* 8, e1002701. <https://doi.org/10.1371/journal.ppat.1002701>

894 Saunte, D.M.L., Gaitanis, G., Hay, R.J., 2020. *Malassezia*-Associated Skin Diseases,
895 the Use of Diagnostics and Treatment. *Front. Cell. Infect. Microbiol.* 10.

896 <https://doi.org/10.3389/fcimb.2020.00112>

897 Savencu, I., Iurian, S., Porfire, A., Bogdan, C., Tomuța, I., 2021. Review of advances in
898 polymeric wound dressing films. *React. Funct. Polym.* 168, 105059.
899 <https://doi.org/https://doi.org/10.1016/j.reactfunctpolym.2021.105059>

900 Serra, E., Saubade, F., Ligorio, C., Whitehead, K., Sloan, A., Williams, D., Hidalgo-
901 Bastida, A., Verran, J., Malic, S., 2020. Methylcellulose Hydrogel with *Melissa*
902 *officinalis* Essential Oil as a Potential Treatment for Oral Candidiasis.
903 *Microorganisms* 8, 215. <https://doi.org/10.3390/microorganisms8020215>

904 Shams-Ghahfarokhi, M., Shokooamiri, M.-R., Amirrajab, N., Moghadasi, B., Ghajari,
905 A., Zeini, F., Sadeghi, G., Razzaghi-Abyaneh, M., 2006. In vitro antifungal
906 activities of *Allium cepa*, *Allium sativum* and ketoconazole against some
907 pathogenic yeasts and dermatophytes. *Fitoterapia* 77, 321–323.
908 <https://doi.org/https://doi.org/10.1016/j.fitote.2006.03.014>

909 Sharma, R., Sharma, G., Sharma, M., 2012. Anti-*Malassezia furfur* activity of essential
910 oils against causal agent of Pityriasis versicolor disease. *African J. Pharm.*
911 *Pharmacol.* 6, 979–983. <https://doi.org/10.5897/AJPP12.097>

912 Sim, J.X.F., Khazandi, M., Chan, W.Y., Trott, D.J., Deo, P., 2019. Antimicrobial
913 activity of thyme oil, oregano oil, thymol and carvacrol against sensitive and
914 resistant microbial isolates from dogs with otitis externa. *Vet. Dermatol.* 30, 524-
915 e159. <https://doi.org/10.1111/vde.12794>

916 Singh, N., Schikowski, T., 2023. Skin diseases and emerging determinants: the need for
917 interactive research. *Br. J. Dermatol.* 188, 457–458.
918 <https://doi.org/10.1093/bjd/ljad008>

919 Siva Sai, C., Mathur, N., 2021. Inhibitory Potential of Essential Oils on *Malassezia*
920 strains by Various Plants. *Biol. Life Sci. Forum* 4, 46.
921 <https://doi.org/10.3390/IECPS2020-08838>

922 Soliman, S.S., Semreen, M.H., El-Keblawy, A.A., Abdullah, A., Uppuluri, P., Ibrahim,
923 A.S., 2017. Assessment of herbal drugs for promising anti-*Candida* activity. *BMC*
924 *Complement. Altern. Med.* 17, 257. <https://doi.org/10.1186/s12906-017-1760-x>

925 Stoleru, E., Dumitriu, R.P., Ailiesei, G.-L., Yilmaz, C., Brebu, M., 2022. Synthesis of
926 Bioactive Materials by In Situ One-Step Direct Loading of *Syzygium aromaticum*
927 Essential Oil into Chitosan-Based Hydrogels. *Gels* 8, 225.
928 <https://doi.org/10.3390/gels8040225>

929 Sugita, T., Boekhout, T., Velegraki, A., Guillot, J., Hađina, S., Cabañes, F.J., 2010.

930 Epidemiology of Malassezia-Related Skin Diseases BT - Malassezia and the Skin:
931 Science and Clinical Practice, in: Boekhout, T., Maysers, P., Guého-Kellermann, E.,
932 Velegraki, A. (Eds.), Malassezia and the Skin. Springer Berlin Heidelberg, Berlin,
933 Heidelberg, pp. 65–119. https://doi.org/10.1007/978-3-642-03616-3_3

934 Talapko, J., Juzbašić, M., Matijević, T., Pustijanac, E., Bekić, S., Kotris, I., Škrlec, I.,
935 2021. *Candida albicans*—The Virulence Factors and Clinical Manifestations of
936 Infection. *J. Fungi* 7, 79. <https://doi.org/10.3390/jof7020079>

937 Tchemtchoua, V.T., Atanasova, G., Aqil, A., Filée, P., Garbacki, N., Vanhooetghem,
938 O., Deroanne, C., Noël, A., Jérôme, C., Nusgens, B., Poumay, Y., Colige, A.,
939 2011. Development of a Chitosan Nanofibrillar Scaffold for Skin Repair and
940 Regeneration. *Biomacromolecules* 12, 3194–3204.
941 <https://doi.org/10.1021/bm200680q>

942 Tomczykowa, M., Wróblewska, M., Winnicka, K., Wieczorek, P., Majewski, P.,
943 Celinska-Janowicz, K., Sawczuk, R., Milyk, W., Tryniszewska, E., Tomczyk, M.,
944 2018. Novel Gel Formulations as Topical Carriers for the Essential Oil of *Bidens*
945 *tripartita* for the Treatment of Candidiasis. *Molecules* 23, 2517.
946 <https://doi.org/10.3390/molecules23102517>

947 Trajano, V.N., Lima, E. de O., Souza, E.L. de, Travassos, A.E.R., 2010. Inhibitory
948 effect of the essential oil from *Eugenia caryophyllata* Thumb leaves on coalho
949 cheese contaminating microorganisms. *Ciência e Tecnol. Aliment.* 30, 1001–1006.

950 Turecka, K., Chylewska, A., Kawiak, A., Waleron, K., 2018. Antifungal Activity and
951 Mechanism of Action of the Co(III) Coordination Complexes With Diamine
952 Chelate Ligands Against Reference and Clinical Strains of *Candida* spp. *Front.*
953 *Microbiol.* 9, 1594. <https://doi.org/10.3389/fmicb.2018.01594>

954 UdDen, N.Z., Shahid, M., 2017. Determination of Bioactive Properties of Different
955 Temperature *Camellia sinensis* (Green Tea). *Am. J. Food Nutr.* 5, 10–18.
956 <https://doi.org/10.12691/ajfn-5-1-2>

957 Vandeputte, P., Ferrari, S., Coste, A., 2012. Antifungal Resistance and New Strategies
958 to Control Fungal Infections. *Int. J. Microbiol.* 2012, 713687.
959 <https://doi.org/10.1155/2012/713687>

960 Veiga, M., Costa, E.M., Silva, S., Pintado, M., 2020. Impact of plant extracts upon
961 human health: A review. *Crit. Rev. Food Sci. Nutr.* 60, 873–886.
962 <https://doi.org/10.1080/10408398.2018.1540969>

963 Velegraki, A., Cafarchia, C., Gaitanis, G., Iatta, R., Boekhout, T., 2015. Malassezia

964 Infections in Humans and Animals: Pathophysiology, Detection, and Treatment.
965 PLOS Pathog. 11, e1004523.

966 Vinciguerra, V., Rojas, F., Tedesco, V., Giusiano, G., Angiolella, L., 2019. Chemical
967 characterization and antifungal activity of *Origanum vulgare*, *Thymus vulgaris*
968 essential oils and carvacrol against *Malassezia furfur*. *Nat. Prod. Res.* 33, 3273–
969 3277. <https://doi.org/10.1080/14786419.2018.1468325>

970 White, T.C., Findley, K., Dawson, T.L., Scheynius, A., Boekhout, T., Cuomo, C.A., Xu,
971 J., Saunders, C.W., 2014. Fungi on the skin: dermatophytes and *Malassezia*. *Cold*
972 *spring Harb. Perspect. Med.* 4, a019802.

973 Williams, D., Kuriyama, T., Silva, S., Malic, S., Lewis, M.A.O., 2011. *Candida*
974 biofilms and oral candidosis: Treatment and prevention. *Periodontol.* 2000 55,
975 250–265. <https://doi.org/10.1111/j.1600-0757.2009.00338.x>

976 Xavier, V., Finimundy, T.C., Heleno, S.A., Amaral, J.S., Calhelha, R.C., Vaz, J., Pires,
977 T.C.S.P., Mediavilla, I., Esteban, L.S., Ferreira, I.C.F.R., Barros, L., 2021.
978 Chemical and Bioactive Characterization of the Essential Oils Obtained from
979 Three Mediterranean Plants. *Molecules* 26, 7472.
980 <https://doi.org/10.3390/molecules26247472>

981 Yang, K., Han, Q., Chen, B., Zheng, Y., Zhang, K., Li, Q., Wang, J., 2018.
982 Antimicrobial hydrogels: promising materials for medical application. *Int. J.*
983 *Nanomedicine* 13, 2217–2263. <https://doi.org/10.2147/IJN.S154748>

984 Zagórska-Dziok, M., Sobczak, M., 2020. Hydrogel-Based Active Substance Release
985 Systems for Cosmetology and Dermatology Application: A Review. *Pharmaceutics*
986 12, 396. <https://doi.org/10.3390/pharmaceutics12050396>

987 Zuzarte, M., Gonçalves, M., Canhoto, J., Salgueiro, L., 2011. Antidermatophytic
988 activity of essential oils. *Sci. Against Microb. Pathog. Commun. Curr. Res.*
989 *Technol. Adv.* 1167–1178.

990
991
992
993
994
995
996
997

Table 1 – Diseases caused by *Malassezia* sp.

Disease	Affected body area(s)	Characteristics/ symptoms/ epidemiology	<i>Malassezia</i> species	References
Pityriasis versicolor or tinea versicolor	Trunk Shoulders	Hyper- or hypo-pigmented (discolored patches) round to oval, flaking lesions. In some cases, can be pruritic. Commonly found in adolescents and young adults. Affects both genders equally. Prevalence: higher in tropical climates than in temperate ones. Often occurs in the summer.	<i>M. furfur</i> <i>M. sympodialis</i> <i>M. globosa</i>	Chandra et al., 2021; Pedrosa et al., 2014; Saunte et al., 2020; Sugita et al., 2010
Folliculitis	Torso Neck Arms	Erythematous, asymptomatic or pruritic papules and pustules. Prevalence: more frequent in tropical and hotter climates; often occurs in association with pregnancy, leukemia, and Hodgkin's disease.	<i>M. furfur</i> <i>M. sympodialis</i>	Chandra et al., 2021; Pedrosa et al., 2014; Saunte et al., 2020; Sugita et al., 2010
Dandruff	Scalp	Common chronic relapsing skin disease. Loosely adherent oily flakes, generally not associated with overt inflammation. Extremely common disease; practically all people are affected at some point in their life.	<i>M. furfur</i> <i>M. obtusa</i> <i>M. sympodialis</i> <i>M. restricta</i> <i>M. globosa</i> <i>M. arunalokei</i>	Chandra et al., 2021; Pedrosa et al., 2014; Saunte et al., 2020
Seborrheic dermatitis	Scalp, Nasolabial folds Ears Eyebrows Chest	Common chronic relapsing skin disease. Inflammation is present with superimposed greasy and yellowish flakes Prevalence: occurs in 1-3% of the general population; 3 times more common in men than in women; increases with age and in the winter.	<i>M. furfur</i> <i>M. obtusa</i> <i>M. yamatoensis</i> <i>M. sympodialis</i> <i>M. restricta</i> <i>M. globosa</i> <i>M. arunalokei</i> <i>M. slooffiae</i>	Chandra et al., 2021; Pedrosa et al., 2014; Saunte et al., 2020; Sugita et al., 2010
Atopic dermatitis	Head Neck	Chronic dermatitis with frequent exacerbations. Prevalence: 1-3% in adults; 10-20% in children. It is more severe in adults than in children.	<i>M. furfur</i> <i>M. obtusa</i> <i>M. japonica</i> <i>M. yamatoensis</i> <i>M. sympodialis</i> <i>M. dermatis</i> <i>M. restricta</i> <i>M. globosa</i>	Chandra et al., 2021; Pedrosa et al., 2014; Saunte et al., 2020; Sugita et al., 2010
Psoriasis	Skin Nails Joints	Chronic skin inflammation. <i>Malassezia</i> sp. does not cause psoriasis but can exacerbate its symptoms. T cell mediated autoimmune disease that results of a combination of genetic and environmental factors. Characterized by epidermal hyperproliferation and hyperkeratinisation. Some <i>Malassezia</i> species are associated with some subtypes of psoriasis.	<i>M. restricta</i> <i>M. globosa</i> <i>M. furfur</i> <i>M. japonica</i>	Chandra et al., 2021
Systemic infections	Blood Urine	Occurs mainly in premature neonates and immunocompromised patients. Clinic signs and symptoms are non-specific. Fever of unknown origin is common.	<i>M. furfur</i> <i>M. packydermatis</i> (in animals)	Chandra et al., 2021; Pedrosa et al., 2018

1002 Table 2 – Minimum inhibitory concentrations of six conventional antifungals against some *Candida*
 1003 species.

	Minimum inhibitory concentration (mM)						References
	Amphotericin B	Fluconazole	Flucytosine 5C	Clotrimazole	Nystatin	Ketoconazole	
<i>C. albicans</i>	0.00108	0.00163	0.00775	-----	-----	0.24086	a), b)
<i>C. tropicalis</i>	0.00108	0.00653	0.00093	-----	0.00054	0.24086	a), c)
<i>C. glabrata</i>	0.00027	0.01306	-----	-----	-----	0.12043	a), b), d)
<i>C. parapsilosis</i>	0.00108	0.00653	0.00194	-----	0.00054	0.06021	a), b), c)
<i>C. krusei</i>	0.00108	0.10448	0.06197	0.00009	0.00108	0.24086	a), b), c), e)

1004 References: a) Pfaller et al., 1994; b) Turecka et al., 2018; c) Arikan et al., 2002; d) Chen et al., 2015; e)

1005 Pelletier et al., 2000

1006

1007 Table 3 – Minimum inhibitory concentrations of seven conventional antifungals against 5 species of

1008 *Malassezia*

	Minimum inhibitory concentration (mM)							References
	Amphotericin B	Terbinafine	Ketoconazole	Fluconazole	Itraconazole	Posaconazole	Voriconazole	
<i>M. furfur</i>	0.00128	0.03157	0.00098	0.13713	0.00035	0.00036	0.00143	a), b)
<i>M. sympodialis</i>	0.00137	0.00395	0.00188	0.02286	0.00071	0.00051	0.00109	b)
<i>M. slooffiae</i>	0.00308	0.00515	0.00013	0.00637	0.00006	0.00004	0.00006	b)
<i>M. pachydermatis</i>	< 0.00006	0.00686	0.00011	0.10448	0.00004	0.00004	0.00017	a), b)
<i>M. dermatis</i>	0.00054	0.00086	<0.00006	0.00163	0.00004	0.00002	0.000009	b)

1009 References: a) Cafarchia et al., 2015; b) Leong et al., 2017

Table 4 – Antimicrobial activity of some essential oils and plant extracts against some *Candida* and *Malassezia* species. The minimum inhibitory concentration (% (w/v)) for each EO/ PE is indicated.

		Yeasts										References
		<i>C. albicans</i>	<i>C. glabrata</i>	<i>C. parapsilosis</i>	<i>C. krusei</i>	<i>C. tropicalis</i>	<i>M. furfur</i>	<i>M. slooffiae</i>	<i>M. sympodialis</i>	<i>M. pachydermatis</i>	<i>M. globosa</i>	
Essential oils	Arborvitae	0.05		0.05								Kozics et al., 2019
	Cassia	0.125		0.125								Kozics et al., 2019
	Clove	0.5		0.5	0.00025	0.0005						Kozics et al., 2019; Trajano et al., 2010
	Eucalyptus	2.5	> 0.2	2.5	> 0.2	> 0.2						(Kozics et al., 2019; Pedroso et al., 2019)
	Lavandula	0.5		0.5	0.5							Carbone et al., 2019
	Lemon	> 0.2	> 0.2	> 0.2	> 0.2	> 0.2	0.09					Pedroso et al., 2019; Sharma et al., 2012
	Lemongrass	0.125		0.125								Kozics et al., 2019
	Tea tree	0.125	> 0.2	0.125	0.2	> 0.2	0.0032		0.25			Hammer et al., 2000; Kozics et al., 2019; Pedroso et al., 2019; Siva Sai and Mathur, 2021
	Myrtle						0.003125	0.003125	0.00625		0.003125	Barac et al., 2018
	Orange	> 0.2	> 0.2	> 0.2	> 0.2	> 0.2	0.22					Pedroso et al., 2019; Sharma et al., 2012
	Oregano	0.05	0.05	0.05	0.1	0.05	0.078			0.06		Kozics et al., 2019; Pedroso et al., 2019; Sim et al., 2019; Vinciguerra et al., 2019
	Rosemary	2.0	> 0.2	0.5	2.0	> 0.2	0.026		0.025	0.036	0.041	Carbone et al., 2019; Khosravi et al., 2016; Pedroso et al., 2019
Spearmint						0.0125	0.01	0.01	0.015	0.025	Khosravi et al., 2016; Siva Sai and Mathur, 2021	
Thyme	0.05		0.05			0.092			0.125		Kozics et al., 2019; Sim et al., 2019; Vinciguerra et al., 2019	
Plant extracts	<i>Allium cepa (cebola)</i>	0.125	0.25	0.25		0.125	8					Shams-Ghahfarokhi et al., 2006
	<i>Allium sativum (alho)</i>	0.0312	0.0312	0.0312		0.0312	0.125					Shams-Ghahfarokhi et al., 2006
	<i>Anacardium occidentale</i>	> 0.2	> 0.2	> 0.2	> 0.2	> 0.2						Pedroso et al., 2019
	<i>Artemisia abrotanum</i>	0.2					0.2	0.2	0.2	0.2	0.2	Brodin et al., 2007
	<i>Asphodelus tenuifolius</i>	0.005										Soliman et al., 2017
	<i>Curcuma longa</i>	> 0.2	> 0.2	> 0.2	> 0.2	> 0.2						Pedroso et al., 2019

	<i>Dittrichia viscosa</i>	0.5		0.5	0.5		0.5			0.5		Rhimi et al., 2018
	<i>Illicium verum</i>						2.5					Lalitha et al., 2008
	<i>Lawsania inermis</i>	0.001										Soliman et al., 2017
	<i>Nyctanthes arbor-tristis</i>						2.5					Lalitha et al., 2008
	<i>Portulaca oleracea</i>	0.001										Soliman et al., 2017
	<i>Punica granatum</i>						2.5					Lalitha et al., 2008
	<i>Salvadora persica</i>	0.0025										Soliman et al., 2017
	<i>Salvia officinalis</i>	0.1	1.0		0.1	0.1						Almeida et al., 2019
	<i>Vochysia divergens</i>	> 0.2	> 0.2	> 0.2	> 0.2							Pedroso et al., 2019

Table 5 – Films with antifungal activity against *Candida* spp.

A) Films incorporated with EOs

Essential oil	Film characteristics				Antifungal activity			References
	Polymer	Plasticizer	Incorporation in nanosystems?	Preparation method	Experimental method	Studied species	Antifungal activity values*	
Eucalyptus	Chitosan	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i> <i>C. parapsilosis</i>	98.86 mm ² 65.94 mm ²	Hafsa et al., 2016
Elicriso	Alginate	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	0.5 mm	Liakos et al., 2014
Cinnamon	Alginate	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	18 mm	Liakos et al., 2014
Lavender	Alginate	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	2 mm	Liakos et al., 2014
Tea tree	Alginate	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	2 mm	Liakos et al., 2014
Peppermint	Alginate	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	6 mm	Liakos et al., 2014
Eucalyptus	Alginate	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	1 mm	Liakos et al., 2014
Lemongrass	Alginate	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	All zone	Liakos et al., 2014
Lemon	Alginate	Glycerol	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	1 mm	Liakos et al., 2014
Clove	Chitosan	-----	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	7 mm	Santos et al., 2019
Tea tree	Chitosan	-----	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i>	9 mm	Santos et al., 2019

B) Films incorporated with PEs

Plant extract	Film characteristics				Antifungal activity			References
	Polymer	Plasticizer	Incorporation in nanosystems?	Preparation method	Experimental method	Studied species	Antifungal activity values	
<i>Salix alba</i>	Chitosan Poly (vinyl pyrrolidone) Poly (N-isopropyl acrylamide)	-----	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i> <i>C. parapsilosis</i> <i>C. tropicalis</i> <i>C. glabrata</i> <i>C. guilliermondii</i>	*4 mm *4 mm *4 mm *5 mm *6 mm	Qureshi et al., 2015
<i>Glycyrrhiza glabra</i>	Starch (Lycocat®)	Glycerol	Yes. Polylactic acid nanoparticles	Solvent casting	Microdilution method	<i>C. albicans</i>	**125.0 µg/mL	Roque et al., 2018
<i>Punica granatum</i>	Starch Poly (vinyl alcohol) Poly (acrylic acid)	Glycerin	No	Solvent casting	Disc diffusion assay	<i>C. albicans</i> <i>C. glabrata</i> <i>C. krusei</i> <i>C. tropicalis</i>	*14.67 ± 0.53 mm *15.50 ± 0.57 mm *20.25 ± 1.70 mm *12.50 ± 1.20	de Paula et al., 2022

Antifungal activity values refer to the values reported on the articles cited on the table. *Results based on the inhibition halo diameter; **Results based on Minimum Inhibitory Concentration (MIC)

Table 6: HGs incorporated with antifungal activity against *Candida* sp.

Essential oil	Hydrogel characteristics			Antifungal activity			References
	Polymer	Plasticizer/ Emulsifier	Incorporation in nanosystems?	Experimental method	Studied species	Antifungal activity values	
<i>Bidens tripartita</i>	Alginate	Glycerol	No	Well diffusion method	<i>C. glabrata</i> <i>C. krusei</i> <i>C. albicans</i> <i>C. tropicalis</i> <i>C. parapsilosis</i>	8.0 mm 9.7 mm 7.7 mm 9.7 mm 10.3 mm	Tomczykowa et al., 2018
<i>Melaleuca alternifolia</i>	Chitosan	Poly-vinyl alcohol/ Na-P	No	Well diffusion method	<i>C. albicans</i>	> 25 mm	Low et al., 2016
<i>Thymus vulgaris</i>	Chitosan/ dextrin	Glycerol/ Tween 80	No	Disc diffusion method	<i>C. albicans</i> <i>C. parapsilosis</i>	38 mm > 40 mm	Dinu et al., 2021
<i>Melissa officinalis</i>	Methylcellulose	Tween 80	No	Disc diffusion method	<i>C. albicans</i>	17.5 mm	Serra et al., 2020
<i>Thymbra capitata</i>	Chitosan	Tween 80	No	Microdilution method	<i>C. glabrata</i> <i>C. krusei</i> <i>C. albicans</i> <i>C. tropicalis</i> <i>C. parapsilosis</i>	125 mg/mL < 15.7 mg/mL 125 mg/mL 31.3 mg/mL < 15.7 mg/mL	De-Oliveira et al., 2013
<i>Nigella sativa</i> <i>Cinnamomun verum</i> <i>Citrus sinensis</i>	Mucilage		No	Microdilution method	<i>C. albicans</i>	3.125 mg/mL	Mirzaii et al., 2021
<i>Syzygium aromaticum</i>	Chitosan	Tween 80	No	Percentage of inhibition	<i>C. albicans</i>	60%	Stoleru et al., 2022
<i>Cymbopogon citratus</i>	Carbopol 940		Yes. Nanosponges of ethyl cellulose	In vivo test with rats	<i>C. albicans</i>	Decrease in fungal cells concentration	Aldawsari et al., 2015
<i>Thymus vulgaris</i>	Alginate/ Layered double hydroxides		No	Disc diffusion method	<i>C. albicans</i>	12.5 mm	Boccalon et al., 2020

Figure captions

Figure 1: Virulence factors of *Candida* spp. and *Malassezia* spp. Sources: (Angiolella et al., 2017b; Figueredo et al., 2013; Hort and Mayser, 2010; Pedrosa et al., 2014; Ro and Dawson, 2006; Williams et al., 2011)

Supplementary figure 1: Classification of hydrogels